UNSPSC 51363003: Carbromal

This classification denotes a sedative and hypnotic with the molecular formula C7H13BrN2O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 0Y299JY9V3, chemically known as urea, (2-bromo-ethylbutyryl)- but generally known as carbromal, which bears US NIH Compound Identifier 6488. European Medicines Agency schedules Carbromal in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06617MIG. The term CARBROMAL is an International Non-Proprietary Name.

UNSPSC 51363003 Carbromal (Commodity) does not reflect the actual pharmaceutical procurement activity posted under this code. Recent state and local solicitations tagged to this code address naloxone and drug deactivation systems, generic pharmaceuticals and OTC products, and direct-to-manufacturer prescription programs — none of which are carbromal, a sedative-hypnotic drug rarely procured by modern state or local health systems. The mismatch suggests either misclassification in the issuing bodies' taxonomy or archival residue from legacy pharmaceutical codes. State and local governments buying under this code designation are focused on community health support, multistate cooperative pharmaceutical purchasing, and pharmacy benefit program modernization rather than carbromal procurement specifically.

The three recent opportunities span Seminole County, Florida (IFB for naloxone and drug deactivation systems, due July 26, 2023), the Texas Health and Human Services Commission (RFI for direct-to-manufacturer prescription capabilities, posted April 3, 2026), and MMCAP — the Minnesota Multistate Cooperative Purchasing Alliance administered by the Minnesota Department of Administration (RFP for generic multi-source pharmaceuticals and OTC products, due March 26, 2026, with performance across participating state and local facilities including Oregon). Activity is concentrated in the Southeast and Upper Midwest, with Texas involvement in exploratory market research. Given the code's apparent misalignment with current state and local pharmaceutical demand and the sparse recent opportunity record, this code warrants close vendor classification review before pursuing activity under it.